Palivizumab (Synagis®)

Louis Bont*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Palivizumab is a humanized monoclonal antibody directed against the respiratory syncytial virus (RSV) F glycoprotein. It is delivered by monthly intramuscular injection during the RSV season. It is indicated for prematurely born infants up to gestational age 35 weeks and children with congenital heart disease to prevent hospital admission by RSV infection. Palivizumab has been shown to prevent recurrent wheeze in the first year of life in otherwise healthy preterm gestational age 33-35 weeks.

Original languageEnglish
Title of host publicationApproved Therapeutic Antibodies and in vivo Diagnostics
PublisherWiley-Blackwell
Pages1825-1854
Number of pages30
Volume4-4
ISBN (Electronic)9783527682423
ISBN (Print)9783527329373
DOIs
Publication statusPublished - 3 Dec 2014

Keywords

  • Bronchiolitis
  • Fusion
  • Infants
  • Non-human target
  • Respiratory syncytial virus
  • Wheeze

Fingerprint

Dive into the research topics of 'Palivizumab (Synagis®)'. Together they form a unique fingerprint.

Cite this